Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious disease of the liver.Wegovy can be used for patients suffering from noncirrhotic metabolic dysfunction-associated steatohepatitis,

Novo Nordisk A/S's Wegovy received Food and Drug Administration approval to treat metabolic-associated steatohepatitis in adults with moderate to advanced scar tissue in the liver.

"It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen.